Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304)
Paz-Ares, L. G. Felip, E. Ahn, M. J. Blackhall, Fiona H Borghaei, H. Cho, B. C. Johnson, M. L. Ramalingam, S. S. Reck, M. Zhang, A.
Paz-Ares, L. G.
Felip, E.
Ahn, M. J.
Blackhall, Fiona H
Borghaei, H.
Cho, B. C.
Johnson, M. L.
Ramalingam, S. S.
Reck, M.
Zhang, A.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Paz-Ares LG, Felip E, Ahn MJ, Blackhall FH, Borghaei H, Cho BC, et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005482.